Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5206775
Max Phase: Preclinical
Molecular Formula: C42H43F3N10O7
Molecular Weight: 856.86
Associated Items:
ID: ALA5206775
Max Phase: Preclinical
Molecular Formula: C42H43F3N10O7
Molecular Weight: 856.86
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(CCOCCNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cc3OC)ncc2C(F)(F)F)c1
Standard InChI: InChI=1S/C42H43F3N10O7/c1-3-34(56)48-25-6-4-7-26(22-25)49-37-29(42(43,44)45)24-47-41(52-37)50-30-11-10-27(23-33(30)61-2)54-17-15-53(16-18-54)19-21-62-20-14-46-31-9-5-8-28-36(31)40(60)55(39(28)59)32-12-13-35(57)51-38(32)58/h3-11,22-24,32,46H,1,12-21H2,2H3,(H,48,56)(H,51,57,58)(H2,47,49,50,52)
Standard InChI Key: IRLRGBUCUIJYPP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 856.86 | Molecular Weight (Monoisotopic): 856.3268 | AlogP: 4.77 | #Rotatable Bonds: 16 |
Polar Surface Area: 199.46 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 17 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.59 | CX Basic pKa: 7.64 | CX LogP: 4.79 | CX LogD: 4.35 |
Aromatic Rings: 4 | Heavy Atoms: 62 | QED Weighted: 0.06 | Np Likeness Score: -1.21 |
1. Li Q, Guo Q, Wang S, Wan S, Li Z, Zhang J, Wu X.. (2022) Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686., 238 [PMID:35594654] [10.1016/j.ejmech.2022.114455] |
Source(1):